Capital Research & Management Co has recently announced that it has increased stake in Agilon Health Inc (NYSE:AGL) by 0.11%. After grabbing 51.41 million shares, the institutional investor is now in possession of 57682.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 12.68% having worth around $925.3 million. Moreover, Morgan Stanley Investment Managem increased its share by 3.53 million to have a control over 43.18 million shares. And Wellington Management Co. LLP raised its holdings to 3.16 million shares by acquiring 41.32 million shares or 10.19% of the stake.
Agilon Health Inc (AGL) concluded trading on 12/07/23 at a closing price of $11.06, with 2.8 million shares of worth about $30.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.31% during that period and on Thursday the price saw a loss of about -0.45%. Currently the company’s common shares owned by public are about 412.38M shares, out of which, 300.07M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 17 analysts are covering the AGL stock and their offered price forecasts bring an average price target of $20.71. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $26.00 and could fall to a lowest price of $12.00. The stock’s current price level is 46.6% above of average price target set by the analysts, while a rise to estimated low would result in gain of 7.83% for the stock. However, touching the estimated high of $26.00 would mean a gain of 57.46% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 129 times over the past 12 months. They bought 1,288,765 shares in 69 of the transactions. In 60 selling transactions, insiders dumped 95,615,479 shares.
American Funds New Economy Fund, Vanguard Health Care Fund, and American Funds AMCAP Fund are the top 3 mutual funds which are holding stakes in Agilon Health Inc American Funds New Economy Fund is currently holding 19.87 million shares of worth totaling $357.75 million. The company recently came buying 0.1 million shares which brought its stake up to 4.90% of the company’s outstanding shares. Vanguard Health Care Fund bought 4.78 million shares, after which its hold over company’s outstanding shares expand to 4.70%, leaving 19.04 million shares with the mutual fund that have a worth of about $342.77 million. American Funds AMCAP Fund, after buying 17.05 million shares, have now control over 4.21% of the stake in the company. It holds 3.7 million shares of worth $306.92 million.
Agilon Health Inc (NYSE: AGL) started trading at $11.00, below -$0.11 from concluding price of the previous day. However, the stock later moved at a day high price of 11.19, or with a loss of -0.45%. Stock saw a price change of 4.14% in past 5 days and over the past one month there was a price change of -19.09%. Year-to-date (YTD), AGL shares are showing a performance of -31.47% which decreased to -37.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.41 but also hit the highest price of $29.44 during that period. The average intraday trading volume for Agilon Health Inc shares is 2.97 million. The stock is currently trading -4.02% below its 20-day simple moving average (SMA20), while that difference is down -27.94% for SMA50 and it goes to -43.79% lower than SMA200.
Capital Research & Management Co acquired 51.41 million shares of Agilon Health Inc having value of about $925.3 million. Data submitted at the U.S SEC by Capital Research & Management Co revealed that the firm now holds 57682.0 shares in the company valued at close to $637962.92, or have control over 0.11% stake in the company. Agilon Health Inc (NYSE: AGL) currently have 412.38M outstanding shares and institutions hold larger chunk of about 86.99% of that. Holding of mutual funds in the company is about 49.33% while other institutional holders and individual stake holders have control over 68.35% and 18.77% of the stake respectively.
The stock has a current market capitalization of $4.49B and its 3Y-monthly beta is at 0.45. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 1.50 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGL, volatility over the week remained 3.53% while standing at 5.28% over the month.
Analysts are in expectations that Agilon Health Inc (AGL) stock would likely to be making an EPS of -$0.13 in the current quarter, while forecast for next quarter EPS is $0.06 and it is $0.02 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.17 which is -$0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.14 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.22% while it is estimated to increase by 135.32% in next year.
Analysts at 17 brokerage firms have issued recommendations for the Agilon Health Inc (AGL)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.35. Out of those 17 Wall Street analysts, 14 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on December 06, 2023 offering a Mkt outperform rating for the stock and assigned a target price of $18 to it.
